Positive results for Avexa
Monday, 16 March, 2009
Melbourne biotech Avexa has reported positive results from its ongoing Phase IIb trial of apricitabine (ATC) in patients with HIV.
Apricitabine is also in Phase III trials for HIV patients with resistance to common antiretrovirals. Interim results in this trial are expected shortly.
The Phase IIb trial is an open label trial for people who have failed previous HIV treatments such as 3TC. After almost two years on the trial, no resistance to ATC has been identified and no serious adverse events have been reported.
Over 85 per cent of patients have HIV loads below detectable levels and CD4 cells on average were over 500 microlitres, the company said.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
